Patent On AIDS Medicine Denied In India

Printer-friendly versionPrinter-friendly version
A decision by the Indian Patent Office to reject a patent on an AIDS drug last week has drawn acclaim from civil society and Indian generic pharmaceutical industries.

The decision was not based on a controversial article of Indian law aimed at preventing patent extensions but rather on the grounds of non-inventiveness. Abbott Laboratories, meanwhile, presented Intellectual Property Watch with justification for its Indian patent request.
The HIV combination drug ritonavir/lopinavir was
Full Story: Patent On AIDS Medicine Denied In India